VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | Benefit of migraine prevention with erenumab

Stewart Tepper • 24 May 2020
EAN 2020
Headache Antibodies Erenumab
STRIVE Prevention Treatment Trial Updates

Stewart Tepper, MD, Professor of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, highlights the benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Stewart Tepper

5:55
Increased placebo response over time in migraine preventive trials
Stewart Tepper • 17 Jun 2022
20:54
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic
Stewart Tepper • 24 May 2020
9:29
CONQUER: galcanezumab in treatment-resistant migraine
Stewart Tepper • 24 May 2020
4:17
Assessing the efficacy of fremanezumab on interictal migraine related burden
Stewart Tepper • 17 Jun 2022

Related Videos

5:45
New European Academy of Neurology guidelines for cluster headache treatment
Rigmor Hojland Jensen • 19 Oct 2023
1:36
New cluster headache treatments are needed to better meet the needs of patients
Rigmor Hojland Jensen • 19 Oct 2023
3:17
Diagnostic criteria for trigeminal autonomic cephalalgias
Elizabeth Leroux • 18 Oct 2023
2:25
Challenges facing trigeminal autonomic cephalalgia diagnosis
Elizabeth Leroux • 18 Oct 2023
The content of VJNeurology is intended for healthcare professionals